{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T05:03:05Z","timestamp":1764306185508,"version":"3.46.0"},"reference-count":26,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacopsychiatry"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Dose-related reference ranges can be used in therapeutic drug monitoring to\n                        monitor pharmacotherapy. The deviation of a measured serum concentration\n                        from the expected serum concentration at the corresponding dose can thus be\n                        identified early and responded to appropriately. The serum concentrations of\n                        patients treated with cariprazine regularly deviated from this dose-related\n                        reference range. As this is a relatively new drug with only one\n                        recommendation on values for a dose-related reference range, the values were\n                        tested for validity using real-world data.<\/jats:p>\n                  <jats:p>Serum concentrations of 24 patients receiving cariprazine once daily were\n                        analyzed retrospectively. Only patients without pharmacokinetic\n                        abnormalities were included. The measured serum concentrations were compared\n                        with the values of the dose-related reference range in the guidelines of the\n                        Arbeitsgemeinschaft f\u00fcr Neuropsychopharmakologie und Pharmakopsychiatrie\n                        consensus guidelines of 2017 and checked whether a sufficient number of\n                        serum concentrations were within the dose-related reference range.<\/jats:p>\n                  <jats:p>Only 45.8% of the measured serum concentrations were within the dose-related\n                        reference range. The C\/D ratio was 1.58\u00b10.73. Accordingly, a lower value of\n                        0.85 and an upper value of 2.31 were calculated for the updated dose-related\n                        reference range, which is below the currently recommended values.<\/jats:p>\n                  <jats:p>The results suggest that the current values for the dose-related reference\n                        range are too high and require adjustment. The updated dose-related\n                        reference range lies between 0.85 and 2.31, with a mean of 1.58\u00b10.73.<\/jats:p>","DOI":"10.1055\/a-2511-3744","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T18:47:52Z","timestamp":1738176472000},"page":"127-131","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic Drug Monitoring of Cariprazine \u2013 Updated Values for a\n                    Dose-Related Reference Range"],"prefix":"10.1055","volume":"58","author":[{"given":"Fabian","family":"Sattaf","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Psychosomatics and Psychotherapy University\n                    Hospital Frankfurt, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maike","family":"Scherf-Clavel","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Psychosomatics and Psychotherapy, Center of\n                    Mental Health, University Hospital of W\u00fcrzburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Unterecker","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Psychosomatics and Psychotherapy, Center of\n                    Mental Health, University Hospital of W\u00fcrzburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Eckert","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Psychosomatics and Psychotherapy University\n                    Hospital Frankfurt, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Reif","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Psychosomatics and Psychotherapy University\n                    Hospital Frankfurt, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Hahn","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Psychosomatics and Psychotherapy University\n                    Hospital Frankfurt, Germany"},{"name":"Department of Mental Health, Varisano Hospital Frankfurt Hoechst,\n                    Frankfurt, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.24869\/psyd.2020.36","article-title":"Efficacy and safety of cariprazine in acute management of psychiatric disorders:\n                    a meta-analysis of randomized controlled trials","volume":"32","author":"H Cooper","year":"2020","journal-title":"Psychiatr Danub"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.4088\/JCP.14m09081","article-title":"Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania\n                    associated with bipolar I disorder: A double-blind, placebo-controlled\n                    study","volume":"76","author":"J R Calabrese","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4088\/JCP.15m10070","article-title":"Efficacy and safety of adjunctive cariprazine in inadequate responders to\n                    antidepressants: A randomized, double-blind, placebo-controlled study in adult\n                    patients with major depressive disorder","volume":"77","author":"S Durgam","year":"2016","journal-title":"J Clin Psychiatry"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00213-016-4450-3","article-title":"Safety and tolerability of cariprazine in the long-term treatment of\n                    schizophrenia: Results from a 48-week, single-arm, open-label extension\n                    study","volume":"234","author":"S Durgam","year":"2017","journal-title":"Psychopharmacology (Berl)"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/JCP.0000000000000346","article-title":"Efficacy and safety of cariprazine in acute exacerbation of schizophrenia:\n                    Results from an international, phase III clinical trial","volume":"35","author":"J M Kane","year":"2015","journal-title":"J Clin Psychopharmacol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jad.2017.08.040","article-title":"The safety and tolerability of cariprazine in patients with manic or mixed\n                    episodes associated with bipolar I disorder: A 16-week open-label study","volume":"225","author":"T A Ketter","year":"2018","journal-title":"J Affect Disord"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/YIC.0000000000000246","article-title":"Long-term safety and tolerability of cariprazine as adjunctive therapy in major\n                    depressive disorder","volume":"34","author":"E Vieta","year":"2019","journal-title":"Int Clin Psychopharmacol"},{"key":"ref8","first-page":"558","article-title":"Wirkstoffkonzentrationsbestimmungen zur therapieleitung. Erg\u00e4nzung\n                    therapeutischer Referenzbereiche durch dosisbezogene Referenzbereiche","volume":"79","author":"E Haen","year":"2008","journal-title":"Nervenarzt"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1055\/s-0037-1600991","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology:\n                    Update 2017","volume":"51","author":"C Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/FTD.0000000000000582","article-title":"Concentration-effect relationships of psychoactive drugs and the problem to\n                    calculate therapeutic reference ranges","volume":"41","author":"C Hiemke","year":"2019","journal-title":"Ther Drug Monit"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/FTD.0000000000000962","article-title":"Dose-related reference range as a tool in therapeutic drug monitoring","volume":"44","author":"E Haen","year":"2022","journal-title":"Ther Drug Monit"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"15652","DOI":"10.1038\/s41598-019-52164-y","article-title":"Evaluation of the dose-related concentration approach in therapeutic drug\n                    monitoring of diuretics and \u03b2-blockers \u2013 drug classes with low adherence in\n                    antihypertensive therapy","volume":"9","author":"S Ritscher","year":"2019","journal-title":"Sci rep"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2298\/VSP140905005R","article-title":"Tacrolimus concentration\/dose ratio as a therapeutic drug monitoring strategy:\n                    The influence of gender and comedication","volume":"72","author":"N Rancic","year":"2015","journal-title":"Vojnosanit Pregl"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.3389\/fphar.2020.01142","article-title":"The clinical impact of the C0\/D ratio and the CYP3A5 genotype on outcome in\n                    tacrolimus treated kidney transplant recipients","volume":"11","author":"T van Gelder","year":"2020","journal-title":"Front Pharmacol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2147\/DDDT.S95100","article-title":"Clinical pharmacology study of cariprazine (MP-214) in patients with\n                    schizophrenia (12-week treatment)","volume":"10","author":"T Nakamura","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":"AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: Update\n                    2011","volume":"44","author":"C Hiemke","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"ref17","first-page":"001","article-title":"Comparison of dose-related-reference ranges with individual psychotropic drug\n                    serum concentrations in clinical practice \u2013 AGNP consensus guidelines 2011 and\n                    2017","volume":"1","author":"G Hefner","year":"2017","journal-title":"J Pharmacol Pharm Res"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s13318-020-00650-4","article-title":"Population pharmacokinetics of cariprazine and its major metabolites","volume":"46","author":"A Periclou","year":"2021","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4088\/JCP.19cs13169","article-title":"Blood levels to optimize antipsychotic treatment in clinical practice: A joint\n                    consensus statement of the American Society of Clinical Psychopharmacology and\n                    the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft f\u00fcr\n                    Neuropsychopharmakologie und Pharmakopsychiatrie","volume":"81","author":"G Schoretsanitis","year":"2020","journal-title":"J Clin Psychiatry"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/FTD.0000000000001152","article-title":"Recommendation for a therapeutic reference range of cariprazine-a short\n                    communication","volume":"46","author":"F Sattaf","year":"2024","journal-title":"Ther drug monit"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.2147\/DDDT.S188760","article-title":"Preclinical pharmacodynamic and pharmacokinetic characterization of the major\n                    metabolites of cariprazine","volume":"13","author":"B Kiss","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/FTD.0000000000000685","article-title":"Dose-related concentrations of neuroactive\/psychoactive drugs expected in blood\n                    of children and adolescents","volume":"42","author":"S Fekete","year":"2020","journal-title":"Ther Drug Monit"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1080\/15622975.2024.2366235","article-title":"Optimisation of pharmacotherapy in psychiatry through therapeutic drug\n                    monitoring, molecular brain imaging and pharmacogenetic tests: Focus on\n                    antipsychotics","volume":"25","author":"X M Hart","year":"2024","journal-title":"World J Biol Psychiatry"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1046\/j.1365-2710.1999.00246.x","article-title":"Gender-related differences in pharmacokinetics and their clinical\n                    significance","volume":"24","author":"E Tanaka","year":"1999","journal-title":"J Clin Pharm Ther"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3904\/kjim.2009.24.1.1","article-title":"Overview of therapeutic drug monitoring","volume":"24","author":"J S Kang","year":"2009","journal-title":"Korean J Intern Med"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1055\/s-0031-1286285","article-title":"Therapeutic drug monitoring in pharmacovigilance and pharmacotherapy safety","volume":"44","author":"E Haen","year":"2011","journal-title":"Pharmacopsychiatry"}],"container-title":["Pharmacopsychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2511-3744.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T04:49:59Z","timestamp":1764305399000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2511-3744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":26,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2025,4,30]]},"published-print":{"date-parts":[[2025,5]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2511-3744","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0176-3679","1439-0795"],"issn-type":[{"type":"print","value":"0176-3679"},{"type":"electronic","value":"1439-0795"}],"subject":[],"published":{"date-parts":[[2025,1,29]]}}}